Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease adenocarcinoma
Phenotype C0004763|barrett\'s oesophagus
Sentences 9
PubMedID- 22653845 barrett's oesophagus is a precursor of oesophageal adenocarcinoma, via intestinal metaplasia and dysplasia.
PubMedID- 24221456 Background and aims: acid-suppressive medications, particularly proton pump inhibitors (ppis), may decrease the risk of oesophageal adenocarcinoma (oac) in patients with barrett's oesophagus (bo).
PubMedID- 20550712 However, to date this hypothesis remains untested.the 'exercise and the prevention of oesophageal cancer study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with barrett's oesophagus.
PubMedID- 22353776 Observational data have also indicated that statins may have protective effects against the development of cancer, for example, modifying the risk of oesophageal adenocarcinoma in patients with existing barrett's oesophagus [20].
PubMedID- 26311716 Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with barrett's oesophagus.
PubMedID- 20937048 Aim: to assess the effect of 40 mg twice daily esomeprazole (high-dose) on gastric and oesophageal ph and symptoms, and biomarkers relevant to adenocarcinoma, in patients with barrett's oesophagus (bo).
PubMedID- 21143918 There are few clear prognostic indicators of susceptibility to developing oesophageal adenocarcinoma although patients with barrett's oesophagus are thought to be more at risk to developing oesophageal adenocarcinoma.
PubMedID- 25708344 Oesophagectomy is a safe option for early adenocarcinoma arising from barrett's oesophagus.
PubMedID- 25633286 Nsaids, statins, low-dose aspirin and ppis, and the risk of oesophageal adenocarcinoma among patients with barrett's oesophagus: a population-based case-control study.

Page: 1